Table G-29Olanzapine compared with placebo

Domains Pertaining to Strength of EvidenceMagnitude of EffectStrength of Evidence
Number of Studies; Number of SubjectsRisk of Bias; Design/QualityConsistencyDirectnessPrecisionSummary Effect Size (95% CI)High, Moderate, Low, Insufficient
PTSD Symptom Reduction: CAPS
1; 19Medium; RCTNA, single studyDirectImprecise−12.13 (−23.29 to −0.97)Insufficient
PTSD Symptom Reduction: TOP-8
1; 15Medium; RCTNA, single studyDirectImprecise−6.7 vs. −11.3, (p=NR)Insufficient
PTSD Symptom Reduction: DTS
1; 15Medium; RCTNA, single studyDirectImprecise−34.2 vs. −39.8, p=NRInsufficient
PTSD Symptom Reduction: SPRINT
1; 15Medium, RCTNA, single studyDirectImprecise−13.6 vs. −14.3, p=NRInsufficient
Remission (no longer having symptoms)
0; 0NANANANANAInsufficient
Loss of Diagnosis
0; 0NANANANANAInsufficient
Prevention/reduction of comorbid depression: CES-D
1; 19MediumNA, single studyDirectImprecise−5.25 vs. −4.88, p<0.03Insufficient
Prevention/reduction of comorbid depression
0; 0NANANANANAInsufficient
Quality of Life
0; 0NANANANANAInsufficient
Disability/functional impairment: Sheehan
1; 15MediumNADirectImprecise−7.7 vs. −8.0, (p<0.001)Insufficient
Return to work or return to active duty
0; 0NANANANANAInsufficient

Abbreviations: CI = confidence interval; NA = not applicable; RCT = randomized controlled trial

From: Appendix G, Strength of Evidence

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.